<DOC>
	<DOCNO>NCT00640770</DOCNO>
	<brief_summary>The primary objective study compare performance CYPHER SELECTTM + Sirolimus-eluting Balloon-expandable Coronary Infrapopliteal Stent balloon angioplasty de novo restenotic native knee tibioperoneal , anterior and/or posterior tibial and/or peroneal arterial lesion prospective , multicenter , randomize clinical study .</brief_summary>
	<brief_title>Comparing Angioplasty DES Treatment Subjects With Ischemic Infrapopliteal Arterial Disease</brief_title>
	<detailed_description>This multicenter , prospective , randomize study conduct 18 center Europe . A total 200 subject enter study randomize 1:1 basis either balloon angioplasty CYPHER SELECTTM + Coronary Infrapopliteal Stent infrapopliteal use subject symptomatic peripheral artery disease ( Rutherford 3 , 4 , 5 ) . All subject undergo repeat angiography 12 month assess primary endpoint In-Segment Binary Restenosis . Follow-up visit schedule 6 week , 6 12 month .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Subject must &gt; = 18 &lt; = 85 year old ; Female childbearing potential must negative pregnancy test within 10 day prior index procedure utilize reliable birth control completion 12month angiographic evaluation ; Clinical diagnosis symptomatic critical limb ischemia define Rutherford 3 , 4 , 5 ; Single treatment de novo restenotic ( PTA ) lesion ( ) tibioperoneal trunk , anterior and/or posterior tibial and/or peroneal artery ; A maximum 2 vessel 1 limb may treat study , vessel 1 target lesion , result single risk target lesion ( ) ; In case 1 target lesion locate Tibioperoneal trunk , 2nd target lesion ( applicable ) locate anterior tibial artery ; Additional nontarget lesion ( ) remain nontarget vessel ( ) treat physician 's discretion mean balloon dilation ( ± bailout stenting ) ; The sum total length target lesion maximum 120 mm ; In total maximum 4 stent may implant fully cover maximum 2 target lesion per subject ; Target vessel &gt; = 2.5 &lt; = 3.5 mm diameter ( visual estimate ) ; Target lesion stenosis &gt; 70 % diameter stenosis ( visual estimate ) ; Guidewire must across first ( applicable ) target lesion locate intraluminally within distal vessel study randomization ; Willing comply specify followup evaluation ; Written inform consent prior study procedure . Significant ( &gt; 50 % ) stenoses distal target lesion might require revascularization , impede runoff ; Angiographic evidence thrombus within target vessel ; Thrombolysis within 72 hour prior index procedure ; Lesions suitable stenting ; Lesions ( define stenosis &gt; 75 % ) common external iliac , common superficial femoral popliteal artery . However , intervention TASC A B lesion ( max . 15cm ) restore adequate blood flow , index procedure allow . This intervention must prior treatment study lesion ( ) successful ; Lesions locate bifurcation require treatment branch ( 1 main branch 1 side branch ) ; Required stent placement across within 1 cm knee joint ; artery subject external compression , artery directly subject movement ankle knee joint ; Prior stent ( ) within target vessel ( ) ; Aneurysm SFA popliteal artery ; Requiring popliteal arterial access ; Concomitant hepatic insufficiency , thrombophlebitis , deep venous thrombus , coagulation disorder receive immunosuppressant therapy ; Recent MI stroke &lt; 30 day prior index procedure ; Coronary intervention &lt; 30 day prior index procedure ; Life expectancy le 12 month ; Known suspect active infection time index procedure , exclude infection low extremity wound target limb ; Impaired renal function ( creatinine &gt; 2.5 mg/dl ) ; Known suspected allergy contraindication aspirin , clopidogrel bisulfate ( PlavixÒ ) ticlopidine ( Ticlidâ ) , heparin , stainless steel contrast agent ; The subject currently take Coumarin / Warfarin , opinion investigator , interfere subject 's participation study ; Any significant medical condition , investigator 's opinion , may interfere subject 's optimal participation study ; The subject currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>